Literature DB >> 26423423

Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Daniel Delitto1, Chelsey Perez1, Song Han1, David H Gonzalo2, Kien Pham2, Andrea E Knowlton3, Christina L Graves3, Kevin E Behrns1, Lyle L Moldawer1, Ryan M Thomas1, Chen Liu2, Thomas J George4, Jose G Trevino1, Shannon M Wallet5, Steven J Hughes6.   

Abstract

The cancer microenvironment allows tumor cells to evade immune surveillance through a variety of mechanisms. While interferon-γ (IFNγ) is central to effective antitumor immunity, its effects on the microenvironment are not as clear and have in some cancers been shown to induce immune checkpoint ligands. The heterogeneity of these responses to IFNγ remains poorly characterized in desmoplastic malignancies with minimal inflammatory cell infiltration, such as pancreatic cancer (PC). Thus, the IFNγ response within and on key cells of the PC microenvironment was evaluated. IFNγ induced expression of human leukocyte antigen (HLA) class I and II on PC cell lines, primary pancreatic cancer epithelial cells (PPCE) and patient-derived tumor-associated stroma, concomitant with an upregulation of PDL1 in the absence of CD80 and CD86 expression. As expected, IFNγ also induced high levels of CXCL10 from all cell types. In addition, significantly higher levels of CXCL10 were observed in PC specimens compared to those from chronic pancreatitis, whereby intratumoral CXCL10 concentration was an independent predictor of poor survival. Immunohistochemical analysis revealed a subset of CXCR3-positive cancer cells in over 90 % of PC specimens, as well as on a subset of cultured PC cell lines and PPCE, whereby exposure to CXCL10 induced resistance to the chemotherapeutic gemcitabine. These findings suggest that IFNγ has multiple effects on many cell types within the PC microenvironment that may lead to immune evasion, chemoresistance and shortened survival.

Entities:  

Keywords:  CXCL10; Epithelial cell; Immuno-oncology; Interferon-γ; Pancreatic cancer; Tumor-associated stroma

Mesh:

Substances:

Year:  2015        PMID: 26423423      PMCID: PMC5129167          DOI: 10.1007/s00262-015-1760-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  45 in total

1.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

2.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Authors:  Rafael Winograd; Katelyn T Byrne; Rebecca A Evans; Pamela M Odorizzi; Anders R L Meyer; David L Bajor; Cynthia Clendenin; Ben Z Stanger; Emma E Furth; E John Wherry; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2015-02-12       Impact factor: 11.151

3.  Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.

Authors:  José G Treviño; Monika Verma; Sandeep Singh; Smitha Pillai; Dongyu Zhang; Daniele Pernazza; Said M Sebti; Nicholas J Lawrence; Barbara A Centeno; Srikumar P Chellappan
Journal:  Mol Cancer Ther       Date:  2013-10-09       Impact factor: 6.261

4.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

Review 5.  Pancreatic cancer microenvironment.

Authors:  Jörg Kleeff; Philipp Beckhove; Irene Esposito; Stephan Herzig; Peter E Huber; J Matthias Löhr; Helmut Friess
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

6.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

7.  Identification, culture, and characterization of pancreatic stellate cells in rats and humans.

Authors:  M G Bachem; E Schneider; H Gross; H Weidenbach; R M Schmid; A Menke; M Siech; H Beger; A Grünert; G Adler
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

8.  Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach.

Authors:  Falko Lange; Katja Rateitschak; Brit Fitzner; Ralf Pöhland; Olaf Wolkenhauer; Robert Jaster
Journal:  Mol Cancer       Date:  2011-02-10       Impact factor: 27.401

Review 9.  Desmoplasia and chemoresistance in pancreatic cancer.

Authors:  Marvin Schober; Ralf Jesenofsky; Ralf Faissner; Cornelius Weidenauer; Wolfgang Hagmann; Patrick Michl; Rainer L Heuchel; Stephan L Haas; J-Matthias Löhr
Journal:  Cancers (Basel)       Date:  2014-10-21       Impact factor: 6.639

10.  In vitro Production of IL-6 and IFN-γ is Influenced by Dietary Variables and Predicts Upper Respiratory Tract Infection Incidence and Severity Respectively in Young Adults.

Authors:  Huicui Meng; Yujin Lee; Zhaoyong Ba; Jennifer A Fleming; Emily J Furumoto; Robert F Roberts; Penny M Kris-Etherton; Connie J Rogers
Journal:  Front Immunol       Date:  2015-03-04       Impact factor: 7.561

View more
  15 in total

1.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.

Authors:  Kien Pham; Daniel Delitto; Andrea E Knowlton; Emily R Hartlage; Ricky Madhavan; David H Gonzalo; Ryan M Thomas; Kevin E Behrns; Thomas J George; Steven J Hughes; Shannon M Wallet; Chen Liu; Jose G Trevino
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

2.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

3.  Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.

Authors:  Daniel Delitto; Andrea E Delitto; Bayli B DiVita; Kien Pham; Song Han; Emily R Hartlage; Brittney N Newby; Michael H Gerber; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Thomas J George; Todd M Brusko; Clayton E Mathews; Chen Liu; Jose G Trevino; Steven J Hughes; Shannon M Wallet
Journal:  Cancer Res       Date:  2016-11-18       Impact factor: 12.701

4.  Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model.

Authors:  Zih-Ying Li; Sheng-Yi Chen; Ming-Hong Weng; Gow-Chin Yen
Journal:  J Food Drug Anal       Date:  2021-06-15       Impact factor: 6.157

5.  CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway.

Authors:  Ying Ren; Yue Kai Gu; Zhen Li; Guang Zi Xu; Yang Meng Zhang; Min Xin Dong; Ying Wang; Xi Bing Zhou
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

6.  Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models.

Authors:  Ryan M Thomas; Raad Z Gharaibeh; Josee Gauthier; Mark Beveridge; Jillian L Pope; Maria V Guijarro; Qin Yu; Zhen He; Christina Ohland; Rachel Newsome; Jose Trevino; Steven J Hughes; Mary Reinhard; Kathryn Winglee; Anthony A Fodor; Maria Zajac-Kaye; Christian Jobin
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

7.  Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis.

Authors:  Yongxun Zhuan-Sun; Fengting Huang; Min Feng; Xinbao Zhao; Wenying Chen; Zhe Zhu; Shineng Zhang
Journal:  Onco Targets Ther       Date:  2017-10-16       Impact factor: 4.147

8.  Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.

Authors:  Nobuyoshi Hiraoka; Yoshinori Ino; Shutaro Hori; Rie Yamazaki-Itoh; Chie Naito; Mari Shimasaki; Minoru Esaki; Satoshi Nara; Yoji Kishi; Kazuaki Shimada; Naoya Nakamura; Toshihiko Torigoe; Yuji Heike
Journal:  Cancer Sci       Date:  2020-07-09       Impact factor: 6.716

Review 9.  Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.

Authors:  Chen Liang; Si Shi; Qingcai Meng; Dingkong Liang; Shunrong Ji; Bo Zhang; Yi Qin; Jin Xu; Quanxing Ni; Xianjun Yu
Journal:  Exp Mol Med       Date:  2017-12-01       Impact factor: 8.718

10.  The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma.

Authors:  Song Han; David H Gonzalo; Michael Feely; Daniel Delitto; Kevin E Behrns; Mark Beveridge; DongYu Zhang; Ryan Thomas; Jose G Trevino; Thomas D Schmittgen; Steven J Hughes
Journal:  Oncotarget       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.